Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 417

1.
2.

Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods.

Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS.

Am J Surg Pathol. 2012 Dec;36(12):1761-70. doi: 10.1097/PAS.0b013e318263207c.

PMID:
23026928
3.

Clinical validation of the gastrointestinal NET grading system: Ki67 index criteria of the WHO 2010 classification is appropriate to predict metastasis or recurrence.

Yamaguchi T, Fujimori T, Tomita S, Ichikawa K, Mitomi H, Ohno K, Shida Y, Kato H.

Diagn Pathol. 2013 Apr 22;8:65. doi: 10.1186/1746-1596-8-65.

4.

Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors.

Dhall D, Mertens R, Bresee C, Parakh R, Wang HL, Li M, Dhall G, Colquhoun SD, Ines D, Chung F, Yu R, Nissen NN, Wolin E.

Hum Pathol. 2012 Apr;43(4):489-95. doi: 10.1016/j.humpath.2011.06.011. Epub 2011 Sep 19.

PMID:
21937080
5.

Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors.

Strosberg J, Nasir A, Coppola D, Wick M, Kvols L.

Hum Pathol. 2009 Sep;40(9):1262-8. doi: 10.1016/j.humpath.2009.01.010. Epub 2009 Apr 14.

PMID:
19368957
6.

Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer.

Bubendorf L, Tapia C, Gasser TC, Casella R, Grunder B, Moch H, Mihatsch MJ, Sauter G.

Hum Pathol. 1998 Sep;29(9):949-54.

PMID:
9744310
7.

Expression of p53, Bcl-2, VEGF, Ki67 and PCNA and prognostic significance in hepatocellular carcinoma.

Stroescu C, Dragnea A, Ivanov B, Pechianu C, Herlea V, Sgarbura O, Popescu A, Popescu I.

J Gastrointestin Liver Dis. 2008 Dec;17(4):411-7.

8.

Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors.

Couvelard A, Deschamps L, Ravaud P, Baron G, Sauvanet A, Hentic O, Colnot N, Paradis V, Belghiti J, Bedossa P, Ruszniewski P.

Mod Pathol. 2009 Feb;22(2):273-81. doi: 10.1038/modpathol.2008.177. Epub 2008 Nov 7.

9.

Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease.

Miller HC, Drymousis P, Flora R, Goldin R, Spalding D, Frilling A.

World J Surg. 2014 Jun;38(6):1353-61. doi: 10.1007/s00268-014-2451-0.

PMID:
24493070
10.

Ki-67 cytological index can distinguish well-differentiated from poorly differentiated pancreatic neuroendocrine tumors: a comparative cytohistological study of 53 cases.

Carlinfante G, Baccarini P, Berretti D, Cassetti T, Cavina M, Conigliaro R, De Pellegrin A, Di Tommaso L, Fabbri C, Fornelli A, Frasoldati A, Gardini G, Losi L, Maccio L, Manta R, Pagano N, Sassatelli R, Serra S, Camellini L.

Virchows Arch. 2014 Jul;465(1):49-55. doi: 10.1007/s00428-014-1585-7. Epub 2014 May 8.

PMID:
24807732
11.

The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours.

Foltyn W, Zajęcki W, Marek B, Kajdaniuk D, Siemińska L, Zemczak A, Kos-Kudła B.

Endokrynol Pol. 2012;63(5):362-6.

12.

Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.

Ezziddin S, Attassi M, Yong-Hing CJ, Ahmadzadehfar H, Willinek W, Grünwald F, Guhlke S, Biersack HJ, Sabet A.

J Nucl Med. 2014 Feb;55(2):183-90. doi: 10.2967/jnumed.113.125336. Epub 2014 Jan 16.

13.

KI67 proliferation index in tumors of the upper urinary tract as related to established prognostic factors and long-term survival.

Rey A, Lara PC, Redondo E, Valdés E, Apolinario R.

Arch Esp Urol. 1998 Mar;51(2):204-10.

PMID:
9586325
14.

Variability of Ki67 labeling index in multiple neuroendocrine tumors specimens over the course of the disease.

Singh S, Hallet J, Rowsell C, Law CH.

Eur J Surg Oncol. 2014 Nov;40(11):1517-22. doi: 10.1016/j.ejso.2014.06.016. Epub 2014 Jul 24.

PMID:
25088936
15.

Is a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases?

Weber JC, Nakano H, Bachellier P, Oussoultzoglou E, Inoue K, Shimura H, Wolf P, Chenard-Neu MP, Jaeck D.

Am J Surg. 2001 Jul;182(1):81-8.

PMID:
11532423
16.

Immunohistochemical staining of cytologic smears with MIB-1 helps distinguish low-grade from high-grade neuroendocrine neoplasms.

Lin O, Olgac S, Green I, Zakowski MF, Klimstra DS.

Am J Clin Pathol. 2003 Aug;120(2):209-16.

17.

Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices.

Remes SM, Tuominen VJ, Helin H, Isola J, Arola J.

Am J Surg Pathol. 2012 Sep;36(9):1359-63. doi: 10.1097/PAS.0b013e3182632038.

PMID:
22895268
18.

Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate.

McCall CM, Shi C, Cornish TC, Klimstra DS, Tang LH, Basturk O, Mun LJ, Ellison TA, Wolfgang CL, Choti MA, Schulick RD, Edil BH, Hruban RH.

Am J Surg Pathol. 2013 Nov;37(11):1671-7. doi: 10.1097/PAS.0000000000000089.

19.

Grading the neuroendocrine tumors of the lung: an evidence-based proposal.

Rindi G, Klersy C, Inzani F, Fellegara G, Ampollini L, Ardizzoni A, Campanini N, Carbognani P, De Pas TM, Galetta D, Granone PL, Righi L, Rusca M, Spaggiari L, Tiseo M, Viale G, Volante M, Papotti M, Pelosi G.

Endocr Relat Cancer. 2013 Dec 16;21(1):1-16. doi: 10.1530/ERC-13-0246. Print 2014 Feb.

20.

MIB-1 labeling index in astrocytic tumors--a clinicopathologic study.

Neder L, Colli BO, Machado HR, Carlotti CG Jr, Santos AC, Chimelli L.

Clin Neuropathol. 2004 Nov-Dec;23(6):262-70.

PMID:
15584210
Items per page

Supplemental Content

Write to the Help Desk